LivaNova enters into $225 million incremental revolver agreement

Chicago, March 11 – LivaNova plc entered into a new incremental facility for a $225 million revolver on March 8, according to an 8-K filing with the Securities and Exchange Commission.

The facility is available to be drawn until the fifth anniversary.

Interest is SOFR plus 250 basis points to 350 bps, based on total net leverage. The commitment fee is between 25 bps and 75 bps, in five tiers.

Goldman Sachs Bank USA is the first-lien administrative agent and first-lien collateral agent on the facility dated Aug. 13, 2021.

Goldman Sachs Bank USA, Bank of America, NA, Barclays, Wells Fargo Bank, NA, MUFG Bank, Ltd., Regions Bank and DNB Capital LLC were the lenders.

The agreement replaces a previous $125 million revolving facility.

Proceeds will be used for general corporate purposes.

The medical device manufacturer is based in London.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.